pcn poster

Posters

Effects of Solriamfetol on Cognition in Participants with Cognitive Impairment Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea: SHARP Study Results

The SHARP trial evaluated solriamfetol's effect on cognitive function in patients with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS)-related cognitive impairment. T...

Charles Shinaver , PhD;

10/26/2023

Efficacy and Engagement With a Digital Therapeutic in Patients With Experiential Negative Symptoms of Schizophrenia

Currently, there are no effective pharmacotherapies approved for experiential negative symptoms (ENS) of schizophrenia. Digital therapeutics (DTx) may represent a feasible option given ub...

Brendan Hare , PhD;

10/26/2023

Efficacy and Safety of Iclepertin (BI 425809) in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Cognitive impairment is a major determinant of poor functional outcomes in schizophrenia. Currently, studies testing potential treatments for cognitive impairment have failed to demonstra...

Brianna Goldenstein , PhD;

10/26/2023

Efficacy and Safety of Paliperidone Palmitate 6-Month Formulation: A 3-Year Analysis in Adults With Schizophrenia

This analysis assessed the efficacy and safety of paliperidone palmitate 6-month (PP6M) in adults with schizophrenia who remained relapse free after a 1-year double-blind study (NCT033453...

Christoph U. Correll , MD;

10/26/2023

Efficacy and Safety of Seltorexant in Insomnia Disorder

In a double-blind, randomized, parallel-group, active- and placebo-controlled, 14-day, dose-finding study in adult/elderly subjects with insomnia disorder, the 10 mg and 20 mg dose groups...

Zhiheng Zhang , MS;

10/26/2023

Efficacy and Safety Outcomes When Transitioning to Paliperidone Palmitate 6-Month From Paliperidone Palmitate 1-Month Versus Paliperidone Palmitate 3-Month

This post hoc analysis of a non-inferiority study (NCT03345342) found that adult patients with schizophrenia who transition to palmitate 6-month (PP6M) from either paliperidone palmitate ...

Karen L. Johnston , PharmD;

10/26/2023

Efficacy and Safety Results from the Confirmatory Phase 3 Randomized, Placebo-Controlled Trial of MDMA-Assisted Therapy for Treatment of Chronic PTSD With at Least Moderate Severity

Posttraumatic stress disorder (PTSD) is a serious neuropsychiatric illness for which novel treatment options are urgently needed. This multi-site, randomized, double-blind, confirmatory p...

Berra Yazar-Klosinski , PhD;

10/26/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder Analyzed by Baseline Clinical Characteristics: Post Hoc analysis of a Phase 4, Open-Label Study

This post hoc analysis of a Phase 4, open-label, 8-week study evaluated if baseline clinical characteristics may influence the effect of adjunctive brexpiprazole on patient life engagemen...

Francois Therrien , PharmD;

10/26/2023

Effects of Oxybate on Sleep, Sleep Architecture, and Disrupted Nighttime Sleep

We summarize clinical data on the effects of oxybates on sleep quality, sleep architecture, and disrupted nighttime sleep (DNS) in patients with narcolepsy. Key data from 4 studies on sod...

Thomas Roth , PhD;

10/26/2023

Differences in Stigma Surrounding Treatment for Generalized Anxiety Disorder and Major Depressive Disorder Across Race and Gender in College Students

This study explores the influence of race and sexual orientation on the stigma surrounding the treatment of GAD and MDD in a cohort of college students.

Sujay Singh ;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products